Millions of people suffer from sleep apnea every single night

We will not rest until they sleep peacefully

One Billion

Sleep apnea sufferers worldwide

Current solutions are not working. Continuous positive airway pressure (CPAP) therapy accounts for 85% of diagnosed sleep apnea patients, yet nearly half don’t comply with the therapy. The devices are cumbersome, loud, uncomfortable and overall intrusive.

Eighty Percent

Remain undiagnosed

When untreated, sleep apnea is linked to serious and costly conditions, including drug-resistant hypertension, obesity, congestive heart failure, type-2 diabetes, atrial fibrillation and more.

$150 Billion

Economic impact of sleep apnea in the US

Untreated sleep apnea costs the U.S. approximately $150 billion annually, due to the healthcare costs associated with these untreated conditions, as well as loss of productivity, workplace accidents and motor vehicle accidents.

The Restera Solution

Restera is a clinical-stage medical technology company developing a first-of-its-kind treatment for sleep apnea.

Restera’s intelligent neurostimulation system is designed to address the shortcomings of existing therapies, which are expensive, intrusive and yield low patient compliance rates.

Restera has raised $29.5M in funding since 2020 and is backed by leading investors.

Restera’s Board of Directors have extensive operational and financial experience in medical technologies and life sciences, while its Scientific Advisors hail from top universities and medical institutions, including University of Pennsylvania, Vanderbilt University, Stanford University, Flinders University, and Monash University.